FDA Approves Gilotrif® (Afatinib) As New Oral Treatment Option for Patients with Squamous Cell Carcinoma of the Lung

• Amanda Bridges
• April 25, 2016
• Drugs

Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy. read article »